Tag: Lutetium 177
FDA Approves Novel Radio-peptide Targeted Therapy Clinical Trial for Neuroendocrine Cancer: PRRT (Peptide Receptor Radionuclide Therapy)
August 24, 2010
For the first time in North America, neuroendocrine cancer patients will have the opportunity to participate in a clinical trial of Lutetieum-177 (LU-177)with Octreotate. Ebrahim S. Delpassand, MD, chief executive officer and medical director of…
READ MORECanadian Report Card on Cancer Features Carcinoid and Neuroendocrine Cancers
March 26, 2010
An article by Maureen Coleman, President of the Carcinoid Neuro-Endocrine Tumour Society (CNETS) Canada www.cnetscanada.org, on carcinoid and neuroendocrine cancers is featured in the rare cancers section of the 2009-2010 Report Card on Cancer …
READ MORE
